Ethanol

Autonomix Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation

Retrieved on: 
Tuesday, April 9, 2024

THE WOODLANDS, TX, April 09, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the successful completion of an animal study evaluating the Company’s proprietary catheter-based sensing technology for use in the renal artery.

Key Points: 
  • The preclinical porcine model study was designed to assess the ability of the Company’s catheter-based sensing technology to effectively sense and target individual nerves surrounding the renal artery.
  • These results strongly demonstrate the potential of Autonomix’s sensing technology to successfully locate nerves around the renal artery.
  • These nerves include those responsible for regulating blood pressure and are the target of recently approved renal denervation procedures for hypertension.
  • The successful completion of this preclinical study provides us with confidence in the potential of our sensing technology to ultimately make renal denervation safer, faster, and more effective.

Avina Unveils Plans for Cutting-Edge Sustainable Aviation Fuel Plant in the Midwest, Forges Alliance for Low-Carbon Ethanol Supply

Retrieved on: 
Wednesday, April 3, 2024

The SAF produced will have significantly reduced life cycle carbon emissions compared to conventional jet fuel.

Key Points: 
  • The SAF produced will have significantly reduced life cycle carbon emissions compared to conventional jet fuel.
  • Preliminary Front End Engineering Design (Pre-FEED) for the project is complete and FEED is expected to kick off in Q2 2024.
  • Avina is proactively collaborating with airline customers and other stakeholders to play a key role in meeting this target.
  • Sustainable Aviation Fuels are critical to decarbonizing the aviation sector and the Ethanol-to-Jet production pathway is the most immediate, cost-effective, and scalable option for aviation decarbonization.

Blue Biofuels Makes First Cellulosic Ethanol

Retrieved on: 
Tuesday, March 26, 2024

About Blue Biofuels, Inc.Blue Biofuels is based in Florida and has the goal to produce biofuels through its developed Cellulose-to-Sugar (CTS) technology. CTS is a sustainable, and renewable green energy system with the potential to achieve a near-zero carbon footprint. The CTS process can convert virtually any plant material – grasses, forestry products, and agricultural waste such as sugarcane bagasse and wheat straw -- into sugars and lignin. Sugars are subsequently processed into biofuels, such as ethanol and sustainable aviation fuel, and lignin may be further processed into a variety of products. The CTS process is a patented and proprietary technology wholly owned by Blue Biofuels.

Key Points: 
  • PALM BEACH GARDENS, FL, March 26, 2024 (GLOBE NEWSWIRE) -- Blue Biofuels, Inc. (OTCQB: BIOF).
  • Blue Biofuels Inc. ("BIOF") continues to make substantial strides in advancing its Cellulose-to-Sugar (CTS) technology towards commercial scale.
  • The company has achieved a significant milestone by successfully producing its first batch of cellulosic ethanol, utilizing the cellulosic sugars created from biomass on its CTS pilot line.
  • BIOF is evaluating prospective locations in Florida capable of accommodating both SAF and cellulosic ethanol production facilities.

Farmers Edge and Gevo Enter Collaboration on Climate-Smart Farm-to-Flight Project

Retrieved on: 
Tuesday, April 9, 2024

Farmers Edge Inc. a pure-play digital agriculture company, and Gevo Inc. (NASDAQ: GEVO), a leader in renewable fuels, have entered a collaboration as part of Gevo’s Climate-Smart Farm-to-Flight project that utilizes funding from a U.S. Department of Agriculture (USDA) grant.

Key Points: 
  • Farmers Edge Inc. a pure-play digital agriculture company, and Gevo Inc. (NASDAQ: GEVO), a leader in renewable fuels, have entered a collaboration as part of Gevo’s Climate-Smart Farm-to-Flight project that utilizes funding from a U.S. Department of Agriculture (USDA) grant.
  • Farmers Edge has already been working with growers in Canada on carbon-intensity programs for the past 3 years and will bring their experience to the recruitment and education aspects of the project.
  • Collaborating with growers across three states, Farmers Edge will support in the data capture associated with the qualifying sustainability practices and calculation of field-level CI scores.
  • Farmers Edge is committed to helping growers be the best by digitizing their operations and telling their sustainability story through data.

Global Partners LP Completes Acquisition of Four Liquid Energy Terminals from Gulf Oil

Retrieved on: 
Tuesday, April 9, 2024

Global Partners LP (NYSE: GLP) (“Global” or the “Partnership”) announced today the successful closing of its acquisition of four liquid energy terminals from Gulf Oil Limited Partnership (“Gulf Oil”).

Key Points: 
  • Global Partners LP (NYSE: GLP) (“Global” or the “Partnership”) announced today the successful closing of its acquisition of four liquid energy terminals from Gulf Oil Limited Partnership (“Gulf Oil”).
  • The terminals are strategically located in Chelsea, MA, New Haven, CT, Linden, NJ, and Woodbury, NJ, and will further enhance Global’s position in the energy economy of the Northeast.
  • With a combined shell capacity of approximately 3.0 million barrels, these terminals expand Global’s ability to store and distribute gasoline, distillates, and ethanol.
  • Slifka continued, “We are happy to finalize this acquisition and welcome these terminals into our growing network.

Hennessey Venom F5 Sets Road Car Lap Record at Circuit of The Americas

Retrieved on: 
Monday, March 25, 2024

SEALY, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Hennessey Special Vehicles, the Texas-based hypercar manufacturer, has set a new road car lap record at the Circuit of The Americas (COTA) with a blistering 2:10.90 lap of the 3.41-mile-long racetrack.

Key Points: 
  • Hennessey Venom F5 Revolution hits 193.10 mph on home circuit in Austin, Texas
    SEALY, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Hennessey Special Vehicles, the Texas-based hypercar manufacturer, has set a new road car lap record at the Circuit of The Americas (COTA) with a blistering 2:10.90 lap of the 3.41-mile-long racetrack.
  • Breaking the previous COTA road car lap record* by 0.43 seconds makes the track-focused Hennessey Venom F5 Revolution the fastest ever road-going hypercar around the Texan circuit.
  • Seeing the Venom F5 take the production car lap record at our home circuit has been an important part of our journey with the F5.
  • *The previous COTA production car lap record was set by a Czinger 21C of 2:11.33 on September 23, 2023.

Aemetis Approved by USCIS for $200 million of EB-5 Investment in Biogas, SAF and Carbon Sequestration Projects

Retrieved on: 
Thursday, March 21, 2024

Citizenship and Immigration Services (USCIS) of $200 million of EB-5 program investment for the Riverbank sustainable aviation fuel (SAF) production plant, the dairy renewable natural gas (RNG) project, the carbon sequestration project, and energy efficiency upgrades to the Keyes ethanol plant.

Key Points: 
  • Citizenship and Immigration Services (USCIS) of $200 million of EB-5 program investment for the Riverbank sustainable aviation fuel (SAF) production plant, the dairy renewable natural gas (RNG) project, the carbon sequestration project, and energy efficiency upgrades to the Keyes ethanol plant.
  • The Riverbank plant was recently granted Authority to Construct (ATC) air permits and is designed to produce 78 million gallons per year of SAF for the aviation market.
  • Aemetis has already secured more than $3 billion of contracts to supply airlines with SAF.
  • The Project’s two primary locations are the Aemetis Advanced Fuels Keyes 65 million gallon per year ethanol plant and the Riverbank Industrial Complex.

Alto Ingredients, Inc. Appoints Todd E. Benton as Chief Operating Officer; Michael D. Kandris to Continue to Serve as Director

Retrieved on: 
Thursday, March 21, 2024

Kandris will continue to serve as a special advisor during a transition period ending with his retirement on June 20, 2024 and will remain on the board of directors.

Key Points: 
  • Kandris will continue to serve as a special advisor during a transition period ending with his retirement on June 20, 2024 and will remain on the board of directors.
  • The company has appointed Todd E. Benton to the position of Chief Operating Officer effective April 1, 2024.
  • “We thank Mike for his leadership, dedication and mentorship, and we look forward to his ongoing contributions as a continuing director completing another smooth management transition,” said McGregor.
  • As demands for low-carbon products rise, our upgraded facility will position the Pekin campus as a leading producer for the future.

Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Retrieved on: 
Thursday, March 14, 2024

THE WOODLANDS, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the safe completion of the first three patient procedures for its proof-of-concept (PoC) human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain.

Key Points: 
  • “We are pleased to have safely completed the first patient procedures utilizing RF ablation in a transvascular approach to reduce the pain associated with pancreatic cancer.
  • The Principal Investigator was able to navigate the catheter to the target treatment area and perform the specified ablations with no significant adverse events.
  • The primary objective of the PoC human clinical trial is to successfully ablate relevant somatic nerves and mitigate pain in patients with pancreatic cancer pain utilizing RF ablation in a transvascular approach to the nerves in the region.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the trial.

Kinder Morgan Announces Amy W. Chronis as Nominee for Election to Board of Directors

Retrieved on: 
Monday, April 1, 2024

Kinder Morgan, Inc. (NYSE: KMI) today announced that its board of directors has nominated Amy W. Chronis to stand for election as a director at its annual meeting of stockholders on May 8, 2024.

Key Points: 
  • Kinder Morgan, Inc. (NYSE: KMI) today announced that its board of directors has nominated Amy W. Chronis to stand for election as a director at its annual meeting of stockholders on May 8, 2024.
  • “We are fortunate to be able to nominate Amy Chronis to serve on KMI’s board of directors.
  • Amy will be a valuable addition to our talented board,” said KMI Executive Chairman Richard D. Kinder.
  • Ms. Chronis will stand for election along with KMIs' current directors at the May 8, 2024, annual meeting.